MX2024003886A - Formulación farmacéutica que comprende tacrolimus, método para su preparación y uso. - Google Patents
Formulación farmacéutica que comprende tacrolimus, método para su preparación y uso.Info
- Publication number
- MX2024003886A MX2024003886A MX2024003886A MX2024003886A MX2024003886A MX 2024003886 A MX2024003886 A MX 2024003886A MX 2024003886 A MX2024003886 A MX 2024003886A MX 2024003886 A MX2024003886 A MX 2024003886A MX 2024003886 A MX2024003886 A MX 2024003886A
- Authority
- MX
- Mexico
- Prior art keywords
- preparation
- pharmaceutical formulation
- formulation including
- including tacrolimus
- tacrolimus
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
- A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Transplantation (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Dermatology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GR20210100639A GR1010308B (el) | 2021-09-27 | 2021-09-27 | Φαρμακευτικο σκευασμα που περιλαμβανει τακρολιμους, μεθοδος για την παρασκευη και χρηση αυτου |
| GB2116138.5A GB2612779A (en) | 2021-11-10 | 2021-11-10 | Pharmaceutical formulation comprising Tacrolimus, method for the preparation thereof and use |
| PCT/EP2022/025445 WO2023046321A1 (en) | 2021-09-27 | 2022-09-27 | Pharmaceutical formulation comprising tacrolimus, method for the preparation thereof and use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2024003886A true MX2024003886A (es) | 2024-07-10 |
Family
ID=83902713
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024003886A MX2024003886A (es) | 2021-09-27 | 2022-09-27 | Formulación farmacéutica que comprende tacrolimus, método para su preparación y uso. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20250319028A1 (https=) |
| EP (1) | EP4440550A1 (https=) |
| JP (1) | JP2024536879A (https=) |
| KR (1) | KR20240060874A (https=) |
| AU (1) | AU2022351126A1 (https=) |
| CA (1) | CA3233139A1 (https=) |
| CO (1) | CO2024005380A2 (https=) |
| MX (1) | MX2024003886A (https=) |
| WO (1) | WO2023046321A1 (https=) |
| ZA (1) | ZA202403104B (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN120000593B (zh) * | 2024-12-27 | 2026-03-20 | 广东药科大学 | 一种他克莫司微晶及其制备方法与应用 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006002365A2 (en) | 2004-06-24 | 2006-01-05 | Angiotech International Ag | Microparticles with high loadings of a bioactive agent |
| MX2007011494A (es) | 2005-03-17 | 2007-12-06 | Elan Pharma Int Ltd | Composiciones inyectables de compuestos inmunosupresores nanoparticulados. |
| WO2017173534A1 (en) * | 2016-04-05 | 2017-10-12 | The Hospital For Sick Children | System for delivery of fk506 for enhancing nerve regeneration |
-
2022
- 2022-09-27 JP JP2024519103A patent/JP2024536879A/ja active Pending
- 2022-09-27 AU AU2022351126A patent/AU2022351126A1/en active Pending
- 2022-09-27 MX MX2024003886A patent/MX2024003886A/es unknown
- 2022-09-27 CA CA3233139A patent/CA3233139A1/en active Pending
- 2022-09-27 EP EP22793109.4A patent/EP4440550A1/en active Pending
- 2022-09-27 US US18/695,608 patent/US20250319028A1/en active Pending
- 2022-09-27 WO PCT/EP2022/025445 patent/WO2023046321A1/en not_active Ceased
- 2022-09-27 KR KR1020247014208A patent/KR20240060874A/ko active Pending
-
2024
- 2024-04-22 ZA ZA2024/03104A patent/ZA202403104B/en unknown
- 2024-04-26 CO CONC2024/0005380A patent/CO2024005380A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CO2024005380A2 (es) | 2024-05-30 |
| WO2023046321A1 (en) | 2023-03-30 |
| WO2023046321A8 (en) | 2024-05-30 |
| AU2022351126A1 (en) | 2024-05-09 |
| EP4440550A1 (en) | 2024-10-09 |
| CA3233139A1 (en) | 2023-03-30 |
| KR20240060874A (ko) | 2024-05-08 |
| JP2024536879A (ja) | 2024-10-08 |
| US20250319028A1 (en) | 2025-10-16 |
| ZA202403104B (en) | 2025-01-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201691884A1 (ru) | Получение загруженных пептидом микросфер на основе plga с характеристиками контролированного высвобождения | |
| CY1124369T1 (el) | Συνθεση εμφυτευματος ρισπεριδονης ή/και παλιπεριδονης | |
| MX2018001499A (es) | Sistema para la entrega de polimeros liquidos para la administracion prolongada de farmacos. | |
| NZ607797A (en) | Corticosteroids for the treatment of joint pain | |
| AR126851A2 (es) | Composición para prevenir o tratar diabetes, diabesidad o complicaciones diabéticas | |
| CO2024005380A2 (es) | Formulación farmacéutica que comprende tacrolimus, método para su preparación y uso | |
| MX2022015777A (es) | Un proceso para degradar productos de plastico. | |
| ES2721850T3 (es) | Nanopartículas poliméricas terapéuticas que comprenden alcaloides vinca y procedimientos de fabricación y uso de las mismas | |
| MX359119B (es) | Formulaciones de liberación sostenida para el suministro de proteínas al ojo y métodos para prepararlas. | |
| CU20160164A7 (es) | Un nanocomplejo micelar | |
| AR111190A1 (es) | Composiciones en hidrogel de prodrogas entrecruzadas de ácido hialurónico y métodos relacionados | |
| MX2009010907A (es) | Formulacion del agente activo cargado en nanoparticulas de plga activadas para nano-terapeuticos direccionados para el cancer. | |
| UY38673A (es) | Producto farmacéutico combinado que contiene leuprolido, un polímero biodegradable y gnrh o agonista | |
| MX373189B (es) | Dispersión sólida amorfa que comprende taxano, comprimido que comprende la misma, y método para su preparación. | |
| BR112015022985A2 (pt) | Microesferas de buprenorfina de carga de fármaco alta e método para produção das mesmas | |
| AR097973A1 (es) | FORMULACIÓN FARMACÉUTICA QUE COMPRENDE HORMONA LIBERADORA DE GONADOTROPINA (GnRH), UN AGONISTA DE GnRH O UN ANTAGONISTA DE GnRH Y MÉTODO DE TRATAMIENTO | |
| MX2019013345A (es) | Métodos para el tratamiento de glioblastoma recurrente (rgbm). | |
| MX392770B (es) | Composición farmacéutica de estabilidad mejorada. | |
| EP4356968A3 (en) | Long-acting formulations | |
| PH12013000124A1 (en) | Pharmaceutical microsphere for embolization | |
| CO2024005798A2 (es) | Formulación farmacéutica inyectable de liberación sostenida de levotiroxina y proceso para la preparación de la misma | |
| AR106085A1 (es) | Formulaciones de olanzapina de liberación sostenida | |
| EP4374861A3 (en) | A method for morselizing and/or targeting pharmaceutically active principles to synovial tissue | |
| MX2020000377A (es) | Esterilizacion mediante radiacion de formas de dosis de polimero hipercomprimido. | |
| MX2017015138A (es) | Formulaciones farmaceuticas para liberacion sostenida de ester de sebacoil dinalbufina. |